Content Reviewed By
Reviewed by a board-certified physician (Medical) · Reviewed by a licensed attorney specializing in mass tort litigation (Legal)
Updated March 2026
GalaFLEX Mesh Complications: What Patients Are Reporting
Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated:
75+ Active Cases Reported
Women nationwide are reporting serious complications after GalaFLEX mesh placement during breast lifts, reductions, reconstructions, and augmentation revisions.
Key Facts
- GalaFLEX is a poly-4-hydroxybutyrate (P4HB) bioresorbable surgical mesh.
- It was FDA 510(k) cleared, not approved through the stricter PMA pathway.
- It is marketed to provide soft-tissue support and then naturally resorb.
- Reported injuries include premature degradation, loss of support, chronic pain, and capsular contracture.
- Women report implant displacement, infection, revision surgery, and disfigurement.
- This remains a monitoring stage with growing adverse event attention.
What We Are Monitoring
Complication reports, medical literature, FDA pathway context, and potential future legal developments involving GalaFLEX mesh.
Who Should Pay Closer Attention
- Women who received GalaFLEX mesh during breast reconstruction or cosmetic breast surgery.
- Patients who developed chronic pain, infection, implant failure, capsular contracture, or significant deformity.
- Patients who required corrective or revision surgery after GalaFLEX placement.
Register for Updates
Submit your details to receive updates on GalaFLEX safety monitoring and potential legal activity.
Get Updates